Market News AIOpen the app

MEDP stock news · Medpace Holdings, Inc.

Stories about Medpace Holdings, Inc. (MEDP) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for MEDP

Follow Medpace Holdings, Inc. (MEDP) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MEDP
Free on the App Store and Google Play, or on the web.
  1. Nov 16, 2026, 9:34 AM ET · Market

    Medpace will host a webinar about developing cell and gene therapies with its expert team.

    Neutral

    Medpace announced an upcoming webinar about cell and gene therapy development. It may help sponsors, but reports no new business result, so it does not change the outlook for Medpace.

  2. Oct 23, 2026, 6:18 PM ET · Market

    Barclays keeps its hold rating on Medpace Holdings and bumps up the target price to $675.

    Neutral

    Barclays raised its share-price goal for Medpace but kept its Hold rating. The mixed analyst view does not change the company’s outlook.

  3. Oct 23, 2026, 2:45 PM ET · Market

    UBS changes its price goal for Medpace to $700, up from $673.

    Neutral

    UBS raised its price goal for Medpace but kept its Neutral rating. The note gives no new details about the company's business, so it does not change Medpace's prospects.

  4. Oct 22, 2026, 9:55 AM ET · Results

    Medpace Hldgs shares what happened during their earnings call for the third quarter of 2026.

    Good for MEDP

    Medpace's sales and profit grew, and quarterly study awards reached a record. Strong demand supports its outlook, despite cancellations and planned expansion costs.